M&A Deal Summary

Bristol-Myers Squibb Acquires Amylin Pharmaceuticals

On June 29, 2012, Bristol-Myers Squibb acquired life science company Amylin Pharmaceuticals for 5.3B USD

Acquisition Highlights
  • This is Bristol-Myers Squibb’s 8th transaction in the Life Science sector.
  • This is Bristol-Myers Squibb’s 5th largest (disclosed) transaction.
  • This is Bristol-Myers Squibb’s 8th transaction in the United States.
  • This is Bristol-Myers Squibb’s 3rd transaction in California.

M&A Deal Summary
Date 2012-06-29
Target Amylin Pharmaceuticals
Sector Life Science
Buyer(s) Bristol-Myers Squibb
Deal Type Add-on Acquisition
Deal Value 5.3B USD
Advisor(s) Goldman Sachs
Credit Suisse Investment Banking (Financial)
Skadden, Arps, Slate, Meagher & Flom (Legal)

Target

Amylin Pharmaceuticals

San Diego, California, United States
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company developing drugs for the treatment of diabetes, obesity, and cardiovascular disease.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Bristol-Myers Squibb

Princeton, New Jersey, United States
Category Company
Founded 1887
Sector Life Science
Employees34,100
Revenue 45.0B USD (2023)
DESCRIPTION

Bristol-Myers Squibb is a life science company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes. The majority of Bristol-Myers Squibb's revenue comes from products in the following therapeutic classes: cardiovascular; virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience; and metabolics. Bristol-Myers Squibb was incorporated in 1887 and is based in Princeton, New Jersey.

DEAL STATS #
Overall 8 of 23
Sector (Life Science) 8 of 23
Type (Add-on Acquisition) 7 of 21
State (California) 3 of 9
Country (United States) 8 of 20
Year (2012) 2 of 2
Size (of disclosed) 5 of 19
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2012-01-07 Inhibitex

Alpharetta, Georgia, United States

Inhibitex, Inc. is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s clinical-stage pipeline includes three Phase 2 development programs: INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections, FV-100, a nucleoside inhibitor in development for the reduction of shingles-associated pain, and Aurexis, a humanized monoclonal antibody in development for the treatment of serious S. aureus bloodstream infections.

Buy $2.5B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2014-02-03 Bristol-Myers Squibb - Global Diabetes Business

United States

Bristol-Myers Squibb - Global Diabetes Business engages in manufacturing, discover, develop and deliver innovative medicines for Diabetes.

Sell $2.7B
Mergr

Product

Company

Legal